09.12.14
CHDI Foundation, Inc. has extended its collaboration with Evotec AG through 2017 for the discovery of new treatments for Huntington's disease. CHDI will fund as many as 52 full-time scientists at Evotec for the next three years.
Initiated in 2006, the collaboration has expanded to fully leverage Evotec's integrated neuroscience platform and now further expands the use of Evotec's high-throughput screening and proteomics platforms. Evotec provides a research activities to CHDI, including integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics and protein production.
Dr. Mario Polywka, chief operating officer of Evotec, said, "We are delighted to continue our collaboration with CHDI and the restated extension clearly illustrates that CHDI values our scientific work and dedication of the team. We look forward to continuing working closely with our colleagues at CHDI to rapidly discover novel drugs against Huntington's disease targets."
Dr. Robert Pacifici, chief scientific officer at CHDI, added, "Evotec represents one of our largest and longest standing relationships and continues to be an important strategic partner in our search for effective treatments for Huntington's disease. Their integrated drug discovery capabilities are helping us to discover novel targets and to advance drug candidates towards the clinic and we look forward to continuing to work with Evotec over the coming years."
Initiated in 2006, the collaboration has expanded to fully leverage Evotec's integrated neuroscience platform and now further expands the use of Evotec's high-throughput screening and proteomics platforms. Evotec provides a research activities to CHDI, including integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics and protein production.
Dr. Mario Polywka, chief operating officer of Evotec, said, "We are delighted to continue our collaboration with CHDI and the restated extension clearly illustrates that CHDI values our scientific work and dedication of the team. We look forward to continuing working closely with our colleagues at CHDI to rapidly discover novel drugs against Huntington's disease targets."
Dr. Robert Pacifici, chief scientific officer at CHDI, added, "Evotec represents one of our largest and longest standing relationships and continues to be an important strategic partner in our search for effective treatments for Huntington's disease. Their integrated drug discovery capabilities are helping us to discover novel targets and to advance drug candidates towards the clinic and we look forward to continuing to work with Evotec over the coming years."